Drug giant invests $300 million in 23andMe and the promise of genetics
The pharma company GlaxoSmithKline will team with 23andMe on developing new drugs, it said in a statement.
What: The $300 million investment in 23andMe shows how drug companies are betting on human genetics to decide what medicines to pursue. Hal Barron, Glaxo’s R&D boss, said the deal was part of an effort to speed up the drug search.
The database: It’s huge and getting bigger. 23andMe has DNA data on more than five million people, which it collected by selling them ancestry and health tests.
The business model: 23andMe has been looking to parlay its gene bank into drugs for a while now. It has other partners, like Pfizer, but this investment is the largest so far.
Richard Scheller, head of 23andMe’s drug team, described his company’s efforts as “nascent.” It does not yet have a drug in human testing, for example.
Treating brains: The companies said one of their first projects would be to develop a drug for Parkinson’s disease.
Deep Dive
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
How AI can help us understand how cells work—and help cure diseases
A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.